These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38406517)

  • 21. [New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment].
    Tauveron-Jalenques U; Bay JO
    Bull Cancer; 2023 May; 110(5):476-477. PubMed ID: 36949000
    [No Abstract]   [Full Text] [Related]  

  • 22. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.
    Calabretta E; Hamadani M; Zinzani PL; Caimi P; Carlo-Stella C
    Blood; 2022 Jul; 140(4):303-308. PubMed ID: 35580172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jain N; Stock W; Zeidan A; Atallah E; McCloskey J; Heffner L; Tomlinson B; Bhatnagar B; Feingold J; Ungar D; Chao G; Zhang X; Qin Y; Havenith K; Kantarjian H; Wieduwilt MJ
    Blood Adv; 2020 Feb; 4(3):449-457. PubMed ID: 32012214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.
    Sermer D; Elavalakanar P; Abramson JS; Palomba ML; Salles G; Arnason J
    Blood Rev; 2023 Jan; 57():101002. PubMed ID: 35989138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.
    Alderuccio JP; Sharman JP
    Blood Rev; 2022 Nov; 56():100967. PubMed ID: 35489963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma.
    Lownik J; Boiarsky J; Birhiray R; Merchant A; Mead M
    Clin Cancer Res; 2024 Jul; 30(14):2895-2904. PubMed ID: 38661647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
    J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab.
    Gettman L
    Sr Care Pharm; 2022 Jan; 37(1):9-16. PubMed ID: 34953508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.
    Papageorgiou SG; Thomopoulos TP; Liaskas A; Vassilakopoulos TP
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
    Alderuccio JP; Reis IM; Hamadani M; Nachiappan M; Leslom S; Kahl BS; Ai WZ; Radford J; Solh M; Ardeshna KM; Hess BT; Lunning MA; Zinzani PL; Stathis A; Carlo-Stella C; Lossos IS; Caimi PF; Han S; Yang F; Kuker RA; Moskowitz CH
    Clin Cancer Res; 2024 Jan; 30(1):139-149. PubMed ID: 37855688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
    Hess B; Townsend W; Ai W; Stathis A; Solh M; Alderuccio JP; Ungar D; Liao S; Liao L; Khouri L; Zhang X; Boni J
    AAPS J; 2021 Dec; 24(1):11. PubMed ID: 34893942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
    Messori A; Rivano M; Mengato D; Chiumente M
    Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
    Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
    Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
    Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
    Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma.
    Zhou Y; Zha J; Lin Z; Fang Z; Zeng H; Zhao J; Luo Y; Li Z; Xu B
    Exp Cell Res; 2018 Jan; 362(2):287-292. PubMed ID: 29174982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
    Alderuccio JP; Ai WZ; Radford J; Solh M; Ardeshna KM; Lunning MA; Hess BT; Zinzani PL; Stathis A; Carlo-Stella C; Hamadani M; Kahl BS; Ungar D; Kilavuz T; Yu E; Qin Y; Caimi PF
    Blood Adv; 2022 Aug; 6(16):4736-4739. PubMed ID: 35790100
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.